Table 2.
Modifiable and nonmodifiable risk factors for developing PTDM including nontransplant-related variables.
| Nontransplant variables | ||||||
|---|---|---|---|---|---|---|
| PTDM (+) (n = 61) |
PTDM (-) (n = 389) |
P | OR | 95% CI | ||
| Inferior | Upper | |||||
| Recipient age (years) | 46.2 ± 1.3 | 40.7 ± 0.6 | 0.001 | 1.04 | 1.02 | 1.07 |
| Male (%, n) | 62.3% (38) | 51.5% (232) | 0.69 | 0.89 | 0.51 | 1.56 |
| Non-black (%, n) | 52.5% (32) | 52.9% (206) | 0.94 | 0.98 | 0.57 | 1.68 |
| RRT (%, n) | 96.7% (59) | 92% (358) | 0.21 | 0.39 | 0.09 | 1.68 |
| Mean time on dialysis (months) | 44.6 | 45.1 | 0.21 | 0.99 | 0.99 | 1.00 |
| ADPKD (%, n) | 11.5% (7) | 9% (35) | 0.54 | 0.76 | 0.32 | 1.80 |
| Pretransplant hyperglycaemia (%, n) | 36% (22) | 23.1% (90) | 0.032 | 0.53 | 0.30 | 0.95 |
| Living donor (%, n) | 45.9% (28) | 41.6% (162) | 0.53 | 0.84 | 0.49 | 1.45 |
| Positive CMV serology (%, n) | 85.2% (52) | 87.9% (342) | 0.52 | 1.29 | 0.56 | 2.79 |
| BMI ≥ 25 kg/m2 (%, n) | 57.4% (35) | 27.7% (108) | 0.0001 | 3.50 | 2.01 | 6.09 |
| HLA DR3 (%, n) | 11.5% (7) | 20% (78) | 0.12 | 1.93 | 0.85 | 4.42 |
| HLA A2 (%, n) | 57.3% (35) | 50.1% (195) | 0.29 | 0.75 | 0.43 | 1.29 |
| HLAB35 (%, n) | 18% (11) | 23.6% (92) | 0.33 | 1.41 | 0.70 | 2.82 |
| HLADR4 (%, n) | 27.8% (17) | 21.3% (83) | 0.26 | 0.70 | 0.38 | 1.29 |
| HLADR7 (%, n) | 29.5% (18) | 22.8% (89) | 0.26 | 0.71 | 0.39 | 1.29 |
| HLADR11 (%, n) | 27.8% (17) | 26.4% (103) | 0.82 | 0.93 | 0.51 | 1.70 |
| HLADR13 (%, n) | 32.7% (20) | 27% (105) | 0.35 | 0.76 | 0.42 | 1.35 |